An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors is a phase 1/2, randomised interventional study registered as NCT07806058 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 140 participants, started 2026-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: HRS-7172 + AG + SHR-1316; HRS-7172 + AG + SHR-1316;; HRS-7172 + AG;; HRS-7172 + AG + SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642;; HRS-717 + HRS-4642+SHR-1316;. Conditions listed: Pancreatic Cancer. Primary outcome: RDE in advanced pancreatic cancer with RAS mutation or amplification; Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria); ORR assessed by the investigator. Pancreatic eligibility wording from the registry: "Locally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing". Sites: China. No results are recorded here; the registry entry is the source.